A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen
This study will compare PF-00299804 given orally on continuous schedule to the approved drug, erlotinib, in patients whose non-small cell lung cancer has progressed after chemotherapy; patients will be randomized to receive one of these drugs, and followed for efficacy and tolerance of each.
Checked against the public recordLast updated Oct 7, 2015 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Pfizer
- Interventions being studied
- Drug: Erlotinib; Drug: PF-00299804
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * advanced measurable Non-Small Cell Lung Cancer (NSCLC); * progressed after 1-2 prior chemotherapy; * Eastern Cooperative Oncology Group (ECOG) 0-2; * tissue available for future KRAS/ EGFR testing Exclusion Criteria: * prior Epidermal Growth Factor Receptor (EGFR) targeted therapy; * active or untreated Central Nervous System (CNS) metastases;
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Northwest Alabama Cancer CenterMuscle Shoals, Alabama
- Agajanian Institute of Oncology and HematologyMontebello, California
- Bridgeport HospitalBridgeport, Connecticut
- Wittingham Cancer Center @ Norwalk HospitalNorwalk, Connecticut
- Medical Oncology & Hematology, P.C.Waterbury, Connecticut
- Winship Cancer Institute at Grady Health SystemsAtlanta, Georgia
- Winship Cancer Institute, Emory UniversityAtlanta, Georgia
- Winship Cancer Institute at Emory UniversityAtlanta, Georgia
- Winship Cancer Institute of Emory UniversityAtlanta, Georgia
- Winship Cancer Institute, Emory UniversityAtlanta, Georgia
- Augusta Oncology Associates, P.C.Augusta, Georgia
- Augusta Oncology Associates, PCAugusta, Georgia
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 7, 2015. Always confirm current availability with the study team.